Tag:
Clinical Trials
Latest Headlines
Latest Headlines
TheStreet: A roundup of the top drug studies left in 2012
Any forward-looking student of the biotech industry will have to check out Adam Feuerstein's review in TheStreet of 22 Phase II and III clinical trials--21 drugs and one diagnostic test--which are expected to read out by the end of this year.
Lilly posts clean safety data on PhIII diabetes blockbuster hopeful
Eli Lilly CEO John Lechleiter has made it clear that dulaglutide is one of the company's top blockbuster hopefuls in its late-stage pipeline.
The R&D revolution wants you
Getting to mid-stage proof of concept data on a careful budget is now one of the most demanding mandates in the industry. John Carroll will be moderating a breakfast panel on June 19 with a group of experts who will explore just how this trend is reshaping the way drugs are discovered and developed.
Home drug delivery considered a 'key initiative' for Marken
Why go to the clinical trial, when you could bring the trial home to you? Offering a home delivery service for clinical subjects is a concept supply chain service provider Marken is looking at possibly using, as an Outsourcing-Pharma story shows.
Patient recruitment should be a greater priority, drugmakers say in survey
A survey of conducted by market research firm Industry Standard Research shows that nearly 90% of surveyed drugmakers would prefer reaching patient recruitment goals at least 10% faster over cutting Phase II or Phase III trial costs 20%.
Gene IDs fast-onset Parkinson's disease
Some people with Parkinson's disease worsen more quickly, and picking out these would help physicians target early treatment and offer support to the patients and their families. A small study has pinpointed some genetic changes that could help to identify these patients and perhaps create targeted treatments.
Download our eBook 'Supplying global clinical trials: Keys to avoiding costly delays'
Getting clinical trials right, and right the first time, is crucial for biopharma companies, especially as the cost of getting a drug to market is skyrocketing. Matthew Herper estimates in "The...
Newron soars on positive PhIII results, $26M pact for Parkinson's drug
Despite being left at the M&A altar last fall after a key partnership deal collapsed, Newron says it has successfully completed two late-stage studies of its experimental Parkinson's drug.
Lundbeck soars on PhIII success for blockbuster hopeful
Lundbeck shares spiked 9% this morning on the news that three late-stage studies of its new depression drug had delivered the data needed to support upcoming regulatory filings.
Download our eBook 'Supplying global clinical trials: Keys to avoiding costly delays'
Getting clinical trials right, and right the first time, is crucial for biopharma companies, especially as the cost of getting a drug to market is skyrocketing. Matthew Herper estimates in "The...
